Long-acting HIV fusion inhibitor albuvirtide combined with ritonavir-boosted lopinavir for HIV-1-infected patients after failing the first-line antiretroviral therapy: 48-week randomized, controlled, phase 3 non-inferiority TALENT study

•Albuvirtide (ABT) is a novel long-acting HIV fusion inhibitor. •ABT combined with LPV/r was non-inferior to LPV/r based three-drug regimen. •ABT combined with LPV/r showed a good safety profile. •ABT combined with LPV/r showed a trend of improvement in renal function. •ABT might be an interesting alternative option for HIV treatment and prevention.